Table 1. Characteristics of all included studies

Study & pubblicat. Year

Design

Patients

(n)

Country

Median age

(mon.)

Median baseline

CD4 count/

percentage

Median baseline

Viral Load

Treatment

 

Duration

follow-up

(months)

Outcome 1

Survival

Outcome 2

Median

CD4 count/

percentage

Outcome 3

Median

Viral Load

Eley5

2006

Retrospec

Descript

409

(South África)

23

 

11.7%

(7%-17.3%)

CD4 <15% = 66.2%

5.58

(5.14–6.11)

2 NRTIs +

 NNRTI or PI

(naïve/non-naïve)

12

84%

(80-87%)

CD4 < 15% = 10.7%

< 400

copies/ ml = 69.7%

Rouet6

2006

Longitud analysis

78

(Cote d’Ivoire)

78

7.5%

(2.1%-11.1%)

5.37

(5.07–5.99)

2 NRTIs +

NNRTI or PI

(naïve)

42

86%

23.1% 36m

24.8% 42m

3.08 36m

2.64 42m

Zhang7

2007

Prospectiv

Analysis

81

(China)

120 (naïve)

144 (exper)

Naïve:

117 (24-186)

Exper:

193 (97-342)

Naïve:

5.53

(5.18-5.71) Exper:

4.85

(3.72-5.33)

AZT + 3TC + NVP

 

12

_

Naïve:

340 (315-538)

Exper:

318 (132-423)

Naïve:

2.60

(<2.6-4.11) Exper:

4.58

(3.88-5.37)

Reddi8

2007

 

Retrospect cohort study

151

(South Africa)

67

7.4%

(2.1%-13.7%)

_

2 NRTIs +

NNRTI or PI

(naïve/non-naive)

 

12

(3.5-13.5)

90.9%

(84.8-94.6)

At 6 months:

+ 10.2 (5-13.8)

At 12 months:

+ 16.2%

(9.6-20.3)

VL <50c/ml:

84% (6m)

83.3% (12m)

O´Brien3

 2006

Observat study

1184

(8 CRLS)

84

18-59m:

9.9% (6-13.2)

60-156m:

189.5

(73-339)

_

2 NRTIs + NNRTI

(naïve/non-naïve)

12

95%

21.5% (18-59)

517 (60-156)

_

Kline9

2007

Study popolation

414

(Romania)

156

292

(1-1143)

5.1

(<2.6-5.9)

Lopinavir/

Ritonavir containing HAART

(naïve/non-naïve)

48

_

+ 270 cell (p<0.0001)

< 2.6 (72%)

 

 

Song10

2007

 

Observat.

Retrospect

 Study

29

(Kenya)

102

182.3

(± 145.6)

5.11

(± 0.72)

AZT + 3TC + NVP

(naïve)

15

100%

363

(± 369)

3.3

(± 0.38)

Puthanakit11

2007

Descript

Study

107

(Thailand)

91

5.3% (SD 4.9)

5.4 (SD 0.5)

2 NRTIs + NNRTI

(naïve)

48

95%

CD4 >25% = 60%

VL <50 = 70%

VL 50-1000=4%

VL>1000 = 7%

 

Romanelli12

2006

Retrospec. observat. cohort study

43

(Brazil)

29.1

(Triple)

Triple:

20.1%(SD 9.3)

Triple:

5.6 (SD 0.8)

Triple teraphy:

2 NRTIs + NNRTI or PI

(naïve)

12

95.5%

+ 4.0% (triple)

 

 

- 2.5 (triple)

 

George13

2007

Observat.

study popolation

236

(Haiti)

75

12%

(6%-19%)

5.3

(range:no data)

2 NRTIs + NNRTI ot PI

(naive)

24

80%

 

+ 15% CD4<5%

+ 11%

CD4 5-24%

+ 5%

CD4 > 25%

At 12 months

Median VL in undetectable range: 56%

Puthanakit14

2007

Prospectiv

Observat.

192

(Thailand)

90

171 ( ± 289)

5.2% (±  4.9%)

5.4 (± 0.5)

2 NRTIs + NNRTI

(naive)

12

 

94.3%

6 months: 431(±425) ; 13.2% ± 6.8

12months:

 922(± 492) ;

17.2% (± 7.5)

< 50 cop/ml

67.7%

Wamalwa15

2007

Prospectiv

Observat

 

67

(Kenia)

52

288

(101-560)

6.2%

(3.6%-10.3%)

18m-3y:

6.4 (6.0-6.6)

> 3years:

5.8 (5.3-6.3)

2 NRTIs + NNRTI

(naive)

 

6

91%

536 (273-841)

(p<0.001)

15.4% (9 .8-21)

(p< 0.001)

2.2

(p<0.001)

Bolton-Moore16

2007

Open cohort assessment

4875

(Zambia)

81

 

12.9% 

(12.5-13.3%)

300

(138-551)

_

2 NRTIs + NNRTI

(naive)

24

_

24m: 28.4%

(27.4 – 29.4)

_

 Machado17

2007

Longitud. Observat study

29

(Brazil)

69

486

(7-2690)

4.84

(3.0-5.7)

Previuos treatm without PI 13/29 (44.8%)

Previuos treatm

with PI 16/29

( 55.2%)

(non-naive)

 

12

_

65.5% increase CD4 cell count

37.9% complete virol. respons

17.2%

partial virol respons

44.8%

virol failure

 

Janssen18

2007

Observat. Cohort study

212

(Cambodia)

72

6% (2.6-13)

100 (22-273)

_

d4T+3TC+NVP

68.9%

d4T+3TC+EVF

18.8%

AZT+3TC+NVP

12.3%

(naïve/non-naive)

 

12

92%

 

+ 17%

(16.3-30.7)

Undetectable

81%

400-1000

3.7%

>1000

15.5%

Lodha19

2005

Descriptiv

Analysis

26

(North India)

69

 

584 (± 685.9)

_

D4T+3TC+NVP

57.6%

AZT+3TC+NVP

29.6%

d4T+ddI+NVP

7.6%

(naïve)

 

6

96.2%

 

699.8

(± 500.6)

 

_

 

 

 

 

 Nyandiko20

2006

Retrospect

review

279

(Kenya)

72

Orphans:

9% (1-33)

259 (4-942)

Non-orphans:

10% (1-41)

169 (4-1744)

 

_

AZT+3TC+NVP

child < 10kg

d4T+3TC+NVP

child > 10kg

(naïve)

33 (orphaned)

41

(non-orph)

95%

_

_

Puthanakit21

2005

Prospectiv

Study

107

(Thailand)

 NPV: 85.2

EFV:

102

NVP  

4% (1-9%)

≤ 6 years:

61 (38-314)

> 6 years:

46 (30-103)

EFV:

3% (1-10%)

≤ 6 years:

228 (42-538)

> 6 years:

 47 (21-128)

NVP:

5.3 (± 0.5)

EFV:

5.4 (± 0.4)

 

3TC+d4T+NVP

Or

3TC+d4T+EFV

(naive)

 

 

18

 

96.3%

21% (15-26%)

532 (287-709)

 

NVP: 3.1

(± 1.0)

EFV: 3.6

(± 0.5)